Houston: Bristol Myers to Build 600,000 SF Plant

In Houston, Bristol Myers Squibb laid out plans to build a 600,000-SF pharmaceutical manufacturing campus in the Generation Park development in Northeast Houston.

“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”

The new $2.3 billion pharmaceutical plant will create nearly 500 new jobs.

The facility will be backed by a Texas Enterprise Fund grant of $4.9 million that has been extended to Bristol Myers Squibb.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” said Governor Greg Abbott. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

Bristol Myers Squibb will be built in the 4,300-acre Generation Park development, located near Beltway 8 and West Lake Houston Parkway. McCord Development, a Houston firm led by Ryan McCord, is the developer of Generation Park.

Bristol Myers Squibb is the second major pharmaceutical project to land in Generation Park in the last year. In 2025, Eli Lilly and Company laid out plans to build a $6.5 billion pharmaceutical manufacturing facility in Generation Park.

“We proudly welcome Bristol Myers Squibb, another leading global pharmaceutical company, to Generation Park,” said Generation Park Management District Executive Director Jennifer Mott. “This highly competitive process validates the role our site plays as a vital life science asset both in Texas and nationally.”

In Bristol Myers Squibb is a New Jersey, based global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.

Bristol Myers Squibb’s 600,000-SF manufacturing campus in Houston will be “a modular, multi-modal campus designed for flexibility and long-term growth. Its architecture allows new manufacturing capabilities to be brought online rapidly as pipeline and commercial needs evolve,” the company said Monday in a press release. “The campus is also built for adaptability, with configuration flexibility that anticipates future advances in digital integration and automation, ensuring the site remains at the frontier of biopharmaceutical development and manufacturing technology as capabilities continue to evolve. BMS envisions this site growing in scale and capability well beyond its opening configuration.”

The U.S. biopharmaceutical industry directly employed more than one million workers in 2022.

“Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” said Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”